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Synchrotron X-Ray Fluorescence Nanoprobe Reveals Target Sites
for Organo-Osmium Complex in Human Ovarian Cancer Cells
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Abstract: A variety of transition metal complexes exhibit
anticancer activity, but their target sites in cells need to
be identified and mechanisms of action elucidated. Here,
it was found that the sub-cellular distribution of [Os(h6-p-
cym)(Azpy-NMe2)I]
+ (p-cym=p-cymene, Azpy-NMe2=2-(p-
[dimethylamino]phenylazo)pyridine) (1), a promising drug
candidate, can be mapped in human ovarian cancer cells
at pharmacological concentrations using a synchrotron X-
ray fluorescence nanoprobe (SXRFN). SXRFN data for Os,
Zn, Ca, and P, as well as TEM and ICP analysis of mitochon-
drial fractions suggest localization of Os in mitochondria
and not in the nucleus, accompanied by mobilization of
Ca from the endoplasmic reticulum, a signaling event for
cell death. These data are consistent with the ability of
1 to induce rapid bursts of reactive oxygen species and
especially superoxide formed in the first step of O2 reduc-
tion in mitochondria. Such metabolic targeting differs
from the action of Pt drugs, offering promise for combat-
ting Pt resistance, which is a current clinical problem.
The most widely used drugs in cancer chemotherapy are plati-
num complexes, cisplatin, carboplatin, and oxaliplatin. Despite
their success, resistance to platinum is now a clinical problem,
as is the need to reduce side-effects and extend treatment to
a wider range of cancers.[1] These challenges might be rem-
edied by complexes of other second and third-row transition
metals if they have different mechanisms of action from plati-
num, for instance by targeting sites other than nuclear DNA or
by causing distinctly different lesions on DNA. Recently, organ-
ometallic half-sandwich OsII arene complexes have shown
promise.[2] Using phenotypic screening, we discovered high ac-
tivity within a series of OsII arene azopyridine complexes. For
example, [Os(h6-p-cym)(Azpy-NMe2)I]PF6 (where p-cym=p-
cymene and Azpy-NMe2=2-(p-[dimethylamino]phenylazo)pyri-
dine) (1, Scheme 1) is 49V more
potent than cisplatin towards
a range of 809 cancer cell lines, and
not cross-resistant with cisplatin or
oxaliplatin.[3] Identifying the target
sites for metallodrugs in cells is
a challenging task, but is assisted
for precious metals by their normal
absence.
Two promising techniques for characterizing the sub-cellular
distribution of metallodrugs are secondary ion mass spectrom-
etry (SIMS) and synchrotron-based X-ray fluorescence (SXRF).
Importantly, these high resolution multi-element analysis tech-
niques allow simultaneous mapping of essential elements such
as P and Zn in cells. The recent development of nanoscale
probing for SIMS (NanoSIMS) has allowed cellular organelles to
be analyzed. For example, Pt from cisplatin and Triplatin C has
been detected by NanoSIMS (maximum resolution of 80V
80 nm2) in the nucleolus of MCF7 cells,[4] whereas Ru from anti-
metastatic organometallic complexes has been found in mem-
branes or intercellular junctions,[5] and gold phosphine anti-
cancer complexes in the nucleus and cytoplasm.[6] However,
NanoSIMS offers low sensitivity towards second and third-row
transition metals (due to low ionization yield),[7] and requires
treatment of cells with elevated drug concentrations.
SXRF has also been used to investigate anticancer metal
compounds in vivo and in vitro. Thus, the cellular distribution
of Pt, Gd, Ru, Se, and As metallodrugs[8] and Nb, Co, Ti, and V
metallocenes has been explored by micro-SXRF.[9] Pt-based
DNA-intercalators have been found concentrated in the nuclei
of cells, whereas cisplatin is evenly distributed throughout the
cell.[8c] SXRF experiments have suggested that Gd complexes
carrying triphenylphosphonium substituents can localize in the
mitochondria of cells (although mitochondria were not dis-
tinctly resolved in the maps acquired)[8h] and that Zn plays an
important role in the resistance to cisplatin.[8b] However, the
spatial resolution achieved previously by micro-SXRF (from
0.2V0.2 to 1.5V1.5 mm2 beam size) made it difficult to assess
accurately the subcellular localization of metals, especially
within small organelles with sizes ,1 mm (which cannot be re-
solved). It also usually required treatment of cells with ex-
tremely high concentrations of drug (>100 mm), although
more relevant concentrations have been used in some experi-
ments (1–20 mm).[8b,d,i,j]
Newly designed SXRF nanoprobes (SXRFN) now allow ac-
quisition of elemental maps with sub-100V100 nm2 resolu-
tion.[10] For example, SXRFN analysis revealed the localization
of a Ru antimalarial drug within the digestive vacuole of Plas-
modium falciparum-infected erythrocytes (80V80 nm2 spot
size; scanned using a 100V100 nm2 step size).[10a]
Here we use the new nano-imaging beamline ID16A at the
ESRF, capable of focussing the hard X-ray beam size down to
27V37 nm2. This represents a significant reduction in the sur-
face of the spot size compared to previous use, and provides
Scheme 1. Structure of [Os(h6-
p-cym)(Azpy-NMe2)I]
+ (1).
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sufficient resolution for the study of sub-cellular organelles.
Furthermore, the unique flux of about 4V1011 photons per
second available at ID16A allows detection of organometallic
anticancer complexes at medically relevant concentrations in
thin cellular sections.[11]
We acquired SXRFN elemental maps for A2870 human ovari-
an carcinoma cells treated with 1, using an excitation energy
of 17.05 keV and a beam-size of 27V37 nm2 (HVV) in all ex-
periments. Samples were scanned using step sizes of 50V
50 nm2 or 20V20 nm2 (the smallest reported for biological
samples). This sampling is consistent with the resolution of-
fered by the focus (&2 pixel elements per resolution element).
Sample preparation is important for the preservation of biolog-
ically relevant elements in adherent mammalian cells. Initial
maps showed that paraformaldehyde (PFA) preserved the
structure of A2780 cells better than methanol fixation (Fig-
ure S1 in the Supporting Information). Interestingly, recent re-
ports suggest that PFA fixation is also not ideal ; although it
maintains the localization of Zn, it leads to increased elemental
leaching when compared to PFA+glutaraldehyde fixation or
vitrification followed by freeze drying.[12] The appropriate level
of exposure of cells to 1 so as to achieve intracellular SXRFN
detection of Os was optimized using ICP-MS (Table S1). As
a result, Os maps for whole A2780 cells treated for 24 h with
biologically relevant concentrations of 1 (IC50 : 0.16 mm or 6V
IC50 : 1 mm) and fixed with 2% PFA were acquired using a 50V
50 nm2 scan step size and 50 ms dwell time (Figure 1 and Fig-
ure S2 in the Supporting Information). These maps confirmed
that 1 is detectable even at drug concentrations as low as
160 nm. SXRFN maps acquired from 500 nm-thick sections of
Epon-embedded cells (1 mm 1, 24 h; raster scan step sizes 50V
50 nm2 or 20V20 nm2 ; 50 ms dwell time) showed that 1 readily
penetrates cells (Figures 2 and 3 and Figures S4 and S5 in the
Supporting Information). Osmium localization does not overlap
with Zn and there is only marginal overlap with P (Figures 2
and 3; confirmed by co-localization analysis, Figures S6 and
S7). Zinc and P are found mostly in cell nuclei (e.g. , as Zn-
finger proteins).[13] This indicates that 1 is not localized in the
nuclei of treated cells, and suggests that DNA is not a major
target for 1.
Interestingly, Os from 1 appeared to be significantly com-
partmentalized within small organelles in cells, concentrated in
small elliptical areas approximately 270 nm in length (Fig-
ures 1–4 and Figure S8 in the Supporting Information). SXRFN
maps of 3T3 cells with mitochondria labeled with gold have
shown similar patterns.[10c] Additionally, TEM images showed
the existence of dark particles of around 350 nm in length in
treated and 400 nm in untreated cells (Figure S9). These ellipti-
cal particles are similar in size and shape to the mitochondria
of fast-growing tumor cells such as A2780, and to other organ-
elles such as endosomes, lysosomes, and peroxisomes. At-
tempts to identify organelle localization of 1 using Os–Au co-
localization in SXRFN maps with antibody-conjugated nano-
goldTM[14] were unsuccessful due to the low efficiency of anti-
body labeling (data not shown).
Supporting evidence for localization of Os in mitochondria
was obtained by isolating mitochondrial fractions from A2780
Figure 1. XRF maps of Os in whole A2780 ovarian cancer cells treated for
24 h with A) IC50 concentration of 1; B) 1 mm 1. Raster scan: 50V50 nm
2 step
size, 50 ms dwell time. Scale bar 5 mm. Calibration bar in ngmm@2.
Figure 2. XRF maps of a 500 nm thick section of A2780 cells treated for 24 h
with 1 mm 1 showing the cellular distribution of Os, Zn, P, and Ca. Raster
scan: 50V50 nm2 step size, 50 ms dwell time. Scale bar 2 mm. Calibration bar
in ngmm@2.
Figure 3. Co-localization XRF map of a 500 nm-thick section of A2780 cells
treated for 24 h with 1 mm 1 showing the cellular distribution of Os (red), Zn
(green), and Ca (blue). Raster scan: 50V50 nm2 step size, 50 ms dwell time.
Scale bar 5 mm.
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cells and determining their Os content by ICP-MS. This in-
creased from (4:1) to (49:7) ng Os per milligram protein
when the treatment dose was increased from 0.16 mm to 1 mm
1 (Figure S10), whereas no Os was found in the mitochondria
of untreated cells.
Additionally, SXRFN mapping showed that treatment of
A2780 cells with 1 leads to significant perturbations in the cel-
lular localization of bound Ca (Figures 2 and 3 and Figure S5).
Calcium in cells is stored in the endoplasmic reticulum (ER). In-
tracellular levels of “free” Ca are normally very low (ca. 100 nm)
and mobilization of stored Ca2+ is a signalling event leading to
allosteric regulation of proteins and enzymes. High levels of cy-
toplasmic Ca2+ can stimulate mitochondrial activity and play
a key role in apoptosis (programmed cell death), by activating
the caspase chain after mitochondrial overload, as well as
other types of cell death processes such as necrosis or autoph-
agy.[15]
Free Ca2+ normally leaks out of cells after fixation, so only
Ca chelated by proteins or other biomolecules can be detect-
ed. Our elemental maps show that bound Ca is concentrated
in the nucleus in untreated A2780 cells, as it correlates well
with Zn and P (Figure S5 in the Supporting Information). How-
ever, upon treatment of cells with 1 mm of 1 we detect only ex-
tranuclear Ca, which is spread over the cytoplasm. Further-
more, Zn maps and TEM images show dramatic fragmentation
of the nucleus and membrane blebbing (Figures 2 and 3 and
Figure S9). Interestingly, cell-cycle analysis of A2780 treated
with 1 mm 1, shows S-G2/M arrest and abnormally high sub-G0
populations (Figure S11), but Ca is not found in areas with
a high density of Os, suggesting that mitochondrial loading
with Ca might have not occurred (at least not after 24 h;
Figure 4 and Figure S12, highlighted areas).
Complex 1 is relatively inert in chemical reactions but ap-
pears to be activated by glutathione in cancer cells resulting in
initial formation of the hydroxido complex and loss of the
iodido ligand, which is rapidly pumped out (Figure 5).[16] Both
the intact complex and hydroxido metabolite are lipophilic cat-
ions, species often readily taken up by mitochondria.[17] We
have observed rapid bursts of reactive oxygen species (ROS)
and especially superoxide on treatment of cancer cells with
1.[18] Proteins in the inner membrane of mitochondria are
active in electron transport and oxidative phosphorylation and
are rich sources of ROS. Moreover, when GSH (an antioxidant)
in cancer cells is depleted by l-buthionine sulfoximine (l-BSO),
the activity of 1 is enhanced several-fold.[17] Additionally, Ca ho-
meostasis is controlled by cellular levels of ROS, and high
levels of radicals can induce the release of Ca from the ER to
the cytoplasm.[19]
Complex 1 is approximately 49V more active than cisplatin
over a range of 809 cancer cell lines. RNA sequencing and pro-
teomic analysis of A2780 cells treated with 1 have shown a dra-
matic effect on the transcription of the mitochondrial chromo-
some indicative of mitochondrial dysfunction, together with
a fast cellular response involving a mitochondria-linked oxida-
tive stress response pathway (NRF2), and downregulation of
key genes, consistent with ROS production and reduction in
the ability of cells to respond.[3b] The ability of 1 to induce the
release of bound Ca from the nucleus to the cytoplasm, and
cause nuclear fragmentation as well as membrane blebbing
can all be related to mitochondrial damage. Mitochondrial tar-
geting offers a promising new strategy for the design of anti-
cancer complexes. The mitochondria of cancer cells are known
to be defective compared to the mitochondria of normal cells.
Indeed we have detected three mutations in the mitochondrial
DNA of A2780 human ovarian cells, all located in complex
1 (NADH dehydrogenase) of the electron transport chain.[3b]
This difference between normal cells and cancer cells should
provide a basis for selective drug activity towards cancer cells
and reduce unwanted side-effects.
These experiments show that with recent advances in the
design of synchrotron X-ray fluorescence nanoprobes it is now
possible to map the distribution of metallodrugs in small or-
ganelles in cancer cells at pharmacologically relevant concen-
trations, down to nanomolar Os concentrations. This demon-
stration of mitochondrial targeting in ovarian cancer cells, to-
gether with our previous molecular cellular studies,[3b] show
that complex 1 has an unusual mode of action.
Experimental Section
XRF experiments were performed on the ID16A beamline at the
ESRF synchrotron light source. Irradiation of the samples was done
Figure 4. XRF maps of a 500 nm-thick section of A2780 cells treated for 24 h
with 1 mm 1 showing the cellular distribution of Os and Ca. Raster scan:
20V20 nm2 step size, 50 ms dwell time. White ellipses show the absence of
Ca in areas with high density of Os. Scale bar 2 mm. Calibration bar in
ngmm@2. Figure 5. Possible pathways that link intracellular activation of 1 with Ca mo-
bilization, mitochondrial dysfunction, ROS generation, and cell death.
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at 17.05 keV energy and detection was performed using a pair of
6-element silicon drift diode detectors (Sensortech, UK). Scan step
size was fixed at 400V400 nm2 (dwell time 100 ms) for coarse
scans and 50V50 nm2 (dwell time 50 ms) for fine scans (although
a sample was also measured using scan step size of 20V20 nm2).
Spectra were fitted using the free PyMCA software.[20] Due to over-
lap between Zn-ka and Os-La1 emissions, fitting of Zn-kb emission
and deconvolution of the signals were also used to provide quanti-
tative data (Figure S2). The fitting procedure includes an attenua-
tion correction that is significant for low Z elements such as P. It as-
sumes a sample matrix consisting of 500 nm thick EPON. The quan-
titative calibration was determined using a thin film X-ray fluores-
cence 7-element reference sample (AXO Dresden GmbH, Table S2).
The Supporting Information contains details of materials used, cell
culture and preparation for TEM (Figure S9), X-ray phase-contrast
(Figure S3), and XRF (spectrum Figure S2; further elemental maps
Figures S1, S4, S5, S11 and S12), Os uptake (Table S1), size distribu-
tion of Os regions-of-interest (ROIs) (Figure S8), mitochondrial
uptake (Figure S10), cycle analysis (Figure S11), fluorescence cali-
bration data (Table S2), and image analysis (Figures S6 and S7).
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